Danish medical journal · 2024
Establishment of permanent peritoneal PleurX catheter as palliative treatment of malignant ascites.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mortensen Marie Riis, Ngyuen Tue Duy, Madsen Hans Henrik, Meier Michelle
Аннотация
INTRODUCTION: Refractory malignant ascites (RMA) is a manifestation of end-stage cancer disease with a major impact on quality of life due to the symptom burden and need for repeated hospitalisations. We previously described the implantation of the permanent PleurX catheter as a treatment of RMA. The present study aimed to evaluate and describe our experience with the permanent PleurX catheter system in the largest cohort to date.
METHODS: A total of 97 consecutive patients had a PleurX catheter implanted from 2015 to 2021. We retrieved retrospective data on patients and procedures using the patient's medical records.
RESULTS: A total of 96 (99%) of implantations were successful, and all patients had symptom relief. Six patients (6%) experienced minor or moderate adverse events: three due to infection, two due to leakage and one because of hypotension. The mean residual lifetime was 77 days.
CONCLUSIONS: We established that implantation of the permanent peritoneal PleurX catheter is a safe and efficient treatment of RMA. We emphasise the importance of early detection and intervention in the management of RMA by implantation of a permanent peritoneal catheter.
FUNDING: None.
TRIAL REGISTRATION: Not relevant.
METHODS: A total of 97 consecutive patients had a PleurX catheter implanted from 2015 to 2021. We retrieved retrospective data on patients and procedures using the patient's medical records.
RESULTS: A total of 96 (99%) of implantations were successful, and all patients had symptom relief. Six patients (6%) experienced minor or moderate adverse events: three due to infection, two due to leakage and one because of hypotension. The mean residual lifetime was 77 days.
CONCLUSIONS: We established that implantation of the permanent peritoneal PleurX catheter is a safe and efficient treatment of RMA. We emphasise the importance of early detection and intervention in the management of RMA by implantation of a permanent peritoneal catheter.
FUNDING: None.
TRIAL REGISTRATION: Not relevant.